The purpose of this Phase I, single-dose, open-label trial is to evaluate the
pharmacokinetics and safety of ivosidenib (AG-120) in healthy, adult male Japanese and
Caucasian subjects. The study plans to evaluate 3 cohorts of a single oral dose of ivosidenib
(AG-120) in Japanese and Caucasian subjects. Pharmacokinetic sampling will take place
serially through-out the duration of subject participation.